Prevencio

Executive Summary

Prevencio is a U.S.-based diagnostics company that has developed the HART test suite, a panel of AI-powered multi-protein blood tests designed to improve the accuracy and accessibility of cardiovascular disease diagnosis and risk assessment. Unlike traditional diagnostics that often rely on invasive procedures or imprecise risk scores, Prevencio's tests analyze multiple protein biomarkers using machine learning algorithms to detect conditions such as coronary artery disease (CAD) and peripheral artery disease (PAD), and to predict the likelihood of heart attack and stroke. Founded in 2013 and headquartered in Kirkland, Washington, the company aims to enable earlier, less invasive detection of cardiovascular events, potentially reducing healthcare costs and improving patient outcomes. Prevencio's platform represents a shift toward precision medicine in cardiology, addressing a significant unmet need in a market where cardiovascular disease remains the leading cause of death globally. While Prevencio operates in a competitive landscape that includes other liquid biopsy and AI diagnostics companies, its focus on cardiovascular disease and the integration of multiple protein markers differentiates its approach. The company has not disclosed its funding history or current stage, but its commercial availability suggests it has achieved some market traction. Upcoming catalysts could include FDA clearance for expanded indications, such as stroke risk prediction, or the publication of validation studies in peer-reviewed journals. Furthermore, a strategic partnership with a major healthcare provider or pharmaceutical company could accelerate adoption and provide capital for growth. Investors should monitor regulatory milestones and clinical evidence generation, as these will be critical for building credibility and reimbursement coverage. The company's private status limits visibility, but its innovative technology positions it as a potential player in the rapidly evolving diagnostics space.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for expanded HART panel indications (e.g., stroke risk assessment)60% success
• Q3 2026Publication of pivotal clinical validation study in a peer-reviewed cardiology journal70% success
• Q4 2026Announcement of strategic partnership or distribution agreement with a national health system or diagnostic lab50% success